VEGFA and peripheral arterial disease: The broad interpretation that gene therapy for PAD/CLI has failed should be tempered by the approvals and ongoing application of plasmid (p)VEGF and pHGF, respectively, in Russia and Japan, and the significant, albeit limited, efficacies seen for gene therapy on some clinical parameters such as rest pain and ulcer healing.